BidaskClub downgraded shares of Opko Health, Inc. (NASDAQ:OPK) from a hold rating to a sell rating in a research report report published on Saturday.
Several other research analysts have also weighed in on the stock. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a buy rating in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Opko Health from a sell rating to a hold rating in a research report on Thursday, October 26th. Ladenburg Thalmann Financial Services reissued a buy rating and set a $16.00 price target on shares of Opko Health in a research report on Monday, September 25th. J P Morgan Chase & Co cut shares of Opko Health from an overweight rating to a neutral rating and reduced their price target for the stock from $12.00 to $7.00 in a research report on Thursday, September 14th. Finally, Jefferies Group LLC reissued a hold rating and set a $6.50 price target (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $13.97.
Shares of Opko Health (NASDAQ OPK) traded up $0.08 during mid-day trading on Friday, reaching $5.49. 5,750,000 shares of the company’s stock traded hands, compared to its average volume of 4,004,709. The company has a quick ratio of 1.50, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health has a one year low of $5.35 and a one year high of $12.15.
Opko Health (NASDAQ:OPK) last announced its earnings results on Wednesday, November 8th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. Opko Health had a negative return on equity of 5.18% and a negative net margin of 9.45%. The company’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same period last year, the business earned ($0.03) EPS. equities research analysts anticipate that Opko Health will post -0.2 earnings per share for the current fiscal year.
In related news, major shareholder Opko Health, Inc. purchased 655,738 shares of the company’s stock in a transaction on Monday, October 30th. The shares were bought at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the purchase, the insider now directly owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 10,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was bought at an average price of $6.15 per share, for a total transaction of $61,500.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $18,874,048.65. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 1,251,038 shares of company stock worth $5,581,640. 40.19% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the business. Public Employees Retirement Association of Colorado increased its stake in Opko Health by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the company’s stock valued at $483,000 after purchasing an additional 216 shares during the last quarter. Pinnacle Associates Ltd. grew its position in shares of Opko Health by 0.8% during the second quarter. Pinnacle Associates Ltd. now owns 50,000 shares of the company’s stock worth $329,000 after acquiring an additional 397 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Opko Health by 1.7% during the second quarter. Ameriprise Financial Inc. now owns 53,788 shares of the company’s stock worth $354,000 after acquiring an additional 896 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Opko Health by 6.1% during the second quarter. Prudential Financial Inc. now owns 24,511 shares of the company’s stock worth $161,000 after acquiring an additional 1,400 shares during the last quarter. Finally, BB&T Securities LLC grew its position in shares of Opko Health by 7.6% during the second quarter. BB&T Securities LLC now owns 20,600 shares of the company’s stock worth $135,000 after acquiring an additional 1,460 shares during the last quarter. Institutional investors own 22.57% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.